Summary One hundred and fifty-seven patients with usual colorectal cancer were analysed prospectively for DNA-ploidy, DNA-index and S-phase fraction (SPF) using flow cytometry. An abnormal DNA-stemline was observed in 68% of tumours. The patients have been followed for a median of 36 months. In univariate analysis, tumour stage was the most significant prognostic factor. After excluding patients with stage D disease, DNA-aneuploidy was significantly associated with a shorter survival and a shorter disease free survival. SPF, however, did not correlate with prognosis. In multiple samples from the same tumour there was on average a 29% difference between the highest and the lowest SPF indicating considerable heterogeneity in proliferative activity within the tumours. In diploid tumours the variation was even higher. (Shapiro, 1989) . This information has proved useful for supplementing clinical and pathological classification of many malignant diseases (Seckinger et al., 1989 ). An accumulating body of data supports the view that flow cytometric detection of an abnormal DNA content in cells and the degree of DNA abnormality and/or proliferative activity in most malignancies may reflect the degree of malignancy and clinical behaviour (Seckinger et al., 1989) . In reports on DNA-abnormalities in colorectal carcinomas, aneuploidy correlates with lower survival rates than diploidy (Wolley et al., 1982; Armitage et al., 1985; Kokal et al., 1986; Goh et al., 1987; Scott et al., 1987a,b; Quirke et al., 1987; Jones et al., 1988) , although the results are somewhat controversial (Melamed et al., 1986; Schutte et al., 1987; Wiggers et al., 1988) . Also, a high S-phase fraction (SPF) has shown an association with poorer survival (Bauer et al., 1987) .
Traditionally, the classification and staging of colorectal carcinoma has been based on post-surgical histopathological assessment of local tumour invasion depth and the presence of lymph node or distant metastases (Dukes & Bussey, 1958) . Flow cytometric techniques can provide quantitative and objective measurement of tumour DNA abnormalities and proliferative activity (Shapiro, 1989) . This information has proved useful for supplementing clinical and pathological classification of many malignant diseases (Seckinger et al., 1989 ). An accumulating body of data supports the view that flow cytometric detection of an abnormal DNA content in cells and the degree of DNA abnormality and/or proliferative activity in most malignancies may reflect the degree of malignancy and clinical behaviour (Seckinger et al., 1989) . In reports on DNA-abnormalities in colorectal carcinomas, aneuploidy correlates with lower survival rates than diploidy (Wolley et al., 1982; Armitage et al., 1985; Kokal et al., 1986; Goh et al., 1987; Scott et al., 1987a,b; Quirke et al., 1987; Jones et al., 1988) , although the results are somewhat controversial (Melamed et al., 1986; Schutte et al., 1987; Wiggers et al., 1988) . Also, a high S-phase fraction (SPF) has shown an association with poorer survival (Bauer et al., 1987) .
In this study we have analysed prospectively 157 fresh primary colorectal carcinomas obtained at the Second Department of Surgery, Helsinki University Central Hospital and examined the prognostic value of flow cytometry derived DNA data such as DNA-ploidy, DNA index and SPF. This is the largest prospective study to date uding fresh samples of colorectal carcinomas. Also, for the first time, patients with the cancer family syndrome have been segregated from usual carcinoma patients because of their different type of DNA ploidy pattern (Kouri et al., 1990 ).
Materials and methods

Patients
One hundred and fifty-seven patients operated on The criteria for exclusion from cell cycle analysis were overlapping histograms (n = 29), high background debris (n = 4) and high CV (n = 2). The peak ratio of aneuploid tumours was calculated by dividing the counts of the aneuploid GI/Go peak by the counts of the diploid GI/Go peak.
Statistical description and analysis Differences between mean values were analysed using a Student's t test, and differences between frequencies with contingency tables.
For calculation of disease-free survival and overall survival, product limit survival analysis was performed using the BMDP 1 L computer program (Dixon, 1988) . Calculations of the significance of observed differences were performed using the log rank test (Mantel-Cox) . Patients with stage D disease were included in this material for the calculation of overall survival rates, but this category of patients was excluded for the calculation of the disease-free-interval.
The relative prognostic importance of all parameters was investigated using Cox's regression model and the BMDP 2L computer program (Dixon, 1988) . A prognostic variable with two or more categories of outcome is represented by a number of variables and parameters equal to the number of its categories minus one. The reference category was not included as a variable.
Results
Overall 106 of 157 (68%) tumours showed an abnormal DNA stemline (Figure 1 ). Eighty-eight of 157 tumours (56%) were classified as aneuploid, 18 of 157 (12%) as tetraploid and 51 of 157 (32%) as diploid. The DNA-index values ranged from 1.00 to 3.21. Multiple samples were analysed in 81 carcinomas. Sixty-five (80%) of them were homogeneous, and 10 (12%) heterogenous with respect to DNA-ploidy. In addition, six (8%) tumours had detectable biclonal aneuploid stemlines. DNA-cytokinetic analysis was possible in 122 cases. The SPF for these colorectal cancers ranged from 8.5 to 46.6%. The median SPF was estimated to be 22.3%. DNA-aneuploid tumours had a significantly higher SPF as compared with DNA-diploid tumours (27.1%, 17.5%, respectively, P = 0.001). In 44 tumours multiple samples were analysed for SPF. In these tumours, there was an average difference of 29% between the highest and the lowest SPF. The variation in SPF increased significantly with increasing number of samples, especially in diploid tumours (P = 0.019). In diploid tumours with two samples the average difference was 27% (n = 16), but as high as 64% with three or more samples (n = 4). In aneuploid with two samples the average difference was 24% (n = 17), and with three or more samples 28% (n = 7).
Aneuploid tumours were more frequent in male than female patients (Table I ). The frequency of aneuploidy increased with increasing level of direct spread of the primary tumour. However, the presence of lymph node or distant metastasis did not differ by ploidy. Seventy-four per cent of rectal and 63% of colonic tumours were aneuploid. The distribution of DNA-indices however, did not differ by tumour site (Figure 2) .
In univariate analysis of the importance prognostic variables tumour stage was the most important prognostic parameter (Table II) . When the depth of direct spread, presence of lymph nodal or distant metastasis were analysed separately, each one was associated with survival. Patients with aneuploid tumours had a worse prognosis than those with diploid or tetraploid tumours (Table III) , although not statistically significantly. When diploid and tetraploid tumours were grouped together, there was a borderline significant difference in survival as compared with aneuploid tumours (X2 = 3.51, P = 0.061, log rank test). In patients with stage D disease the survival did not correlate with ploidy (Figure 3d) . After excluding these patients the difference in survival between aneuploid and diploid tumours was statistically significant both when tetraploid tumours were grouped into aneuploid or diploid tumours. SPF, PI or peak ratio of aneuploid tumours did not correlate with survival.
Since 14 of the 36 patients with relapsed disease were still alive at the time of analysis, a disease-free survival analysis of patients with stage A-C disease was performed separately (Tables IV and V, Figure 3a-c) . Patients with aneuploid tumours had a significantly shorter disease-free survival than A-C aneuploid tumours had a significantly poorer overall survival as well as disease-free survival than those with diploid and tetraploid tumours. This difference remained significant when tumour stage was included in a multivariate analysis. In the present study only patients with usual colorectal carcinoma and without a history of previous malignancy were included. Recently we have shown that patients with cancer family syndrome have mainly DNA-diploid colorectal carcinomas (Kouri et al., 1990) . Of all colorectal carcinoma patients 5-6% have a cancer family syndrome (Mecklin, 1987) and these patients seem to have a favourable prognosis. Based on these findings CFS patients should be treated separately when analysing DNA ploidy of colorectal cancer. Previously, it has been reported that proximal tumours are more often diploid than distal ones (Rognum et al., 1987 , Scott et al., 1987b , Jones et al., 1988 . Our results support these findings. Even when the patients with known CFS were excluded from this series, only 56% of right-sided tumours were aneuploid in contrast to 67% of left-sided and 74% of rectal tumours. The difference was not, however, statistically significant. Similar to the findings of Rognum et al. (1987) aneuploidy was more frequent in male than female patients. These findings suggest that there may be two or more genetic types of colorectal cancer leading to different types of ploidy pattern. These types could correspond to the two inherited colorectal cancer syndromes: familial adenomatosis and CFS as suggested by Knudson (1989) .
DNA-ploidy had no prognostic value in patients with locally advanced or metastatic (stage D) disease as has been reported previously (Schutte et al., 1987; Rognum et al., 1987) . When the analysis was limited to patients with stage A-C disease, a significant difference in disease-free survival and also in overall survival was observed. In most of the published studies the survival rate of patients with diploid tumours has been 14-27% better than the survival of patients with aneuploid tumours. When compared by stage, the survival difference has usually been observed in patients with lymph nodal metastastasis. This is predictable since the overall number of events, e.g. deaths or relapses, due to cancer is high in stage C tumours. In contrast, more than 90% of patients with stage A disease can be cured.
The limit of defining an aneuploid peak has been shown to affect the results concerning DNA ploidy and survival (Jones et al., 1988) . Classification of DNA-histograms of small aneuploid peaks is especially difficult in samples with a high coefficient of variation, usual in series using paraffin blocks for DNA analysis. The calculation of DNA-index may also be difficult in some cases due to the lack of an internal control. In fresh samples using chicken or trout blood cells as internal controls these problems can be alleviated (Vindel0v et al., 1983) . Previously in two studies (Scott et al., 1987a; Jones et al., 1988) it was found that tumours with large aneuploid peaks had a worse prognosis than those with smaller aneuploid peaks. Both these studies used paraffin embedded archival material for DNA analysis. In our study using fresh samples we could not reproduce these observations. Most probably, a variation between samples from the same tumour would limit the usefulness of peak ratio as a prognostic factor.
Tetraploid tumours had a better prognosis than other aneuploid tumours. Grouping tetraploid and diploid tumours together increased the prognostic value of DNA ploidy. This is in agreement with the findings of Quirke et al. (1987) but disagrees with those of Jones et al. (1988) and Scott et al. (1987a) . In previous studies the frequency of tetraploid tumours has varied from 4% (Kokal et al., 1986) to 24% (Jones et al., 1988) which reflects the difficulties in defining tetraploidy. It would be reasonable to suppose that tumours classified as tetraploid based on DNA-index have a heterogeneous pattern of DNA abnormalities. This would explain the discrepancies found in the literature. SPF or PI did not have a prognostic value in colorectal carcinomas unlike in breast and ovarian carcinomas (Kallioniemi et al., 1988a,b) . This finding did not change when diploid and aneuploid tumours were analysed separately or when SPF was entered as a continuous variable or grouped in two or three categories. In aneuploid tumours even taking the peak ratio into account the SPF was not associated with survival. In most studies on colorectal carcinoma published so far, the cell cycle has not been analysed, probably because of technical difficulties in determining the SPF. In three studies, the prognostic value of SPF or PI has been reported. Bauer et al. (1987) , using paraffin samples, report SPF values in 99% of the analysed samples and showed that SPF is an even more significant prognostic factor than DNA ploidy. Schutte et al. (1987) were able to calculate SPF in 70% of the samples and reported an association between SPF and survival, similar to that of the ploidy level. Quirke et al. (1987) analysed PI only in diploid tumours and diploid areas of aneuploid tumours and found an association between a high PI and a poor survival.
The heterogeneity of colorectal carcinomas seems to be the most important reason for the large variance of SPF. In the present study an average difference of 29% in SPF between samples from the same tumour was observed. The difference was even more pronounced in diploid tumours. The basic problem in cell cycle analysis is the separation between malignant and non-malignant cells. In diploid samples, the percent of malignant cells can vary in different samples making the estimates of SPF less precise. In aneuploid samples with near-diploid peaks, SPF calculation is less accurate due to overlapping cell cycle histograms. Also background debris, especially in paraffin samples, may disturb cell cycle analysis. To eliminate this problem Bauer et al. (1987) electronically subtracted the debris area with suitable software. It seems obvious that for SPF determination to be more accurate in fresh samples, multiple samples should be used. Better methods for separation of malignant cell population are also needed.
In the current prospective study using fresh samples of usual colorectal carcinomas, the results show that DNAaneuploidy is associated with poorer prognosis in patients with stage A-C disease. Tumour stage is, however, the most important prognostic factor. The clinical value of SPF needs to be studied further, especially in methodological aspects. Flow cytometric DNA-analysis may be useful in classifying different subgroups of colorectal carcinomas with different clinicopathological features as shown with cancer family syndrome. This may lead to a better understanding of tumour progression and even to selection of surgically treated patients into new adjuvant treatment protocols.
